ArticleEndocrine2025
TTF1-positive posterior pituitary tumors: a single-center experience of 10 years.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A third ventricular floor-associated TTF-1-positive posterior pituitary tumor: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Posterior Pituitary and Hypothalamic Neuronal Tumors in the 5th WHO Classification: Molecular Insights, Diagnostic Markers, and Clinical Management.International journal of molecular sciences · 2026Review
- Histopathological Types, Clinical Presentation, Imaging Studies, Treatment Strategies, and Prognosis of Posterior Pituitary Tumors: An Updated Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary TTF1-positive posterior pituitary tumors (PPT) are uncommon and frequently misdiagnosed preoperatively. This study aims to describe our experience with PPT, examining clinical, radiological and histopathological data, as well as surgical and clinical outcomes.
methodsWe conducted a retrospective review of medical records from patients treated at a single neurosurgical center between 2013 and 2023. Immunohistochemistry for TTF-1 was performed using AB_1158934.
resultsNine PPT were included: 6 spindle cell oncocytomas (SCO), 2 granular cell tumor (GCT) and 1 pituicytoma. The median age was 53 years (range 34-70), with six (66.7%) patients being male. Most patients presented preoperatively with panhypopituitarism (8 cases), visual impairment (7 cases) and headache (7 cases). The median largest tumor diameter of 2.7 cm (range 1.7-5.4 cm) and PPT appeared isointense on T1W. SCO typically manifested as large intrasellar tumors with suprasellar extension and pronounced contrast-enhancement. GCT and pituicytoma were predominantly suprasellar lesions, with GCT showing a characteristic "star-like crack" pattern. Surgical outcomes varied, with the minority of successful cases involving SCO, known for their hypervascularity and firm consistency.
conclusionPTT constituted 0.6% of sellar/suprasellar surgeries at our center. SCO should be suspected if a large and significant contrast-enhancement lesion is seen, and GCT if there is a suprasellar tumor with a "star-like crack" pattern. Surgical outcomes were not favorable: the majority of cases showed subtotal resection requiring adjuvant radiotherapy. Long-term follow-up is crucial due to the limited curative outcomes observed in most patients.
Indexed as
Identifiers
40175820What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.